Investor's Business Daily on MSN11m
Behind Hims Stock's Roller-Coaster Ride As Weight-Loss Drugs Battle Heats Up
Hims & Hers Health has blazed a red-hot streak, helped by the growing popularity of weight-loss drugs. But after a massive ...
telecareaware.com17h
These just in: drug compounders sue FDA over semaglutide scarcity removal; Sycamore’s Walgreens buy plans begin to show
What the telehealth prescribers can’t do, the compounders are. A major drug compounder association, the Outsourcing Facilities Association, along with member North American Custom Laboratories, LLC, ...
JD Supra19h
FDA Announces End to Semaglutide Shortage, Impacting Compounders and Telehealth Providers Offering Injectable GLP-1 Drugs
Last week, the US Food and Drug Administration (FDA) announced the end of a years-long shortage of semaglutide injection products — a ...
Modern Healthcare19h
GLP-1 compounding pharmacies sue FDA over shortage decision
Outsourcing Facilities Association and North American Custom Laboratories allege the FDA removed semaglutide from its ...
The American Journal of Managed Care19h
Medicare Part D Spending Trends for Type 2 Diabetes Medications
New diabetes medications are pressuring Medicare Part D financially as they drive up prescription drug costs amid rising ...
Becker's Hospital Review1d
Compounding pharmacies sue over semaglutide removal from shortage lis
The lawsuit, filed by the Outsourcing Facilities Association , FarmaKeio Custom Compounding and North American Custom Laboratories in the U.S. District Court for the Northern District of Texas, argues ...
NJBIZ1d
Drug compounders sue FDA over Novo Nordisk’s Ozempic, Wegovy (updated)
Drug compounders aren’t ready to give up their ability to produce off-brand versions of Novo Nordisk’s weight-loss drug ...
Healio1d
Top in endocrinology: Semaglutide shortage ends; rise in diabetes in low-income countries
The FDA recently removed semaglutide from its drug shortage list, which has not been considered commercially available since ...
Novo Nordisk's Ozempic And Wegovy No Longer on FDA Shortage List, Faces Lawsuit Over Decision
A lawsuit challenges the FDA's decision to remove semaglutide from the shortage list, alleging it was arbitrary and harms ...
Amgen Stock: Why I Still Rate It A 'Buy'
Amgen released financial results for the 4th quarter of 2024. Check out why I continue to cover AMGN stock with a 'Buy' ...
Endocrinology Advisor2d
Novo Nordisk’s Wegovy, Ozempic No Longer in Short Supply, According to FDA
The Food and Drug Administration has determined that the shortage of Wegovy® (semaglutide) and Ozempic® (semaglutide) is resolved.